We’re currently spending billions trying to decouple cellular plasticity from malignancy, treating them like separate rooms in the same house. They aren’t. It’s the same door, and it swings both ways.

The dogma of rejuvenation—specifically epigenetic reprogramming—rests on the assumption that we can return a cell to a 'primitive' state of high potential without triggering a total loss of identity. We’ve treated oncogenic risk as a side effect to be managed, rather than a fundamental property of the state we’re trying to achieve. But a 70-year-old body isn’t a blank-slate embryo; it’s a high-entropy, pro-inflammatory landscape. Reintroducing plasticity into a damaged system like that isn't rejuvenation—it’s an invitation to stochastic chaos. Is it possible human lifespan is hard-capped not by oxidative stress or telomere length, but by the maximum duration a multicellular system can remain plastic before it inevitably collapses into a neoplasm?

If the price of 'staying young' is an exponential hike in the probability of a malignant event, we aren’t extending life. We’re just floorboarding the accelerator.

We’re funding the 'reset' buttons—Yamanaka factors, mRNA delivery, and small molecules—while largely ignoring the containment field. We need a massive shift toward synthetic biological guardrails: artificial, orthogonal systems that can monitor and police cell state transitions in real-time. We have to move beyond simple 'reset' protocols and toward spatial-aware governance of the genome. We need collaborators in computational biology who understand that a 'reset' is useless if the system has no structural memory of its correct function. If we can’t engineer a way to decouple rejuvenation from dedifferentiation, we’re just building a faster car with no brakes.

Are we brave enough to admit the 'cure' for aging might be functionally indistinguishable from the mechanism of cancer?